Clin2
NCT06778564Likely a fitNot yet recruiting

CBD (cannabidiol) for early psychosis

PsychosisFirst Episode PsychosisPsychotic DisordersPsychotic Episode

Treatments studied

Part of Mental health clinical trials.

This study tests if adding a CBD medication to your current antipsychotic can improve symptoms in people with schizophrenia or related disorders who started treatment recently but aren't fully better yet.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 3
Enrollment
250 people
Ages
16 years to 40 years
Study type
Interventional

Who can take part

  • Aged 16 to 40 years
  • Currently taking an antipsychotic for at least 3 weeks, but no more than 16 weeks
  • Your current antipsychotic isn't working well enough and your doctor agrees it's safe to add the study drug
  • Diagnosis of schizophrenia, schizoaffective, or schizophreniform disorder
  • Not in remission from your psychosis symptoms
  • Willing to use highly effective birth control if you could become pregnant

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07326124Not yet recruiting· Phase 3
Testing cannabidiol for early psychosis

This trial tests whether adding cannabidiol (CBD) to clozapine improves symptoms in people with early psychosis. It is for those who have been on clozapine for at least 8 weeks and still have some symptoms.

Berlin
NCT07245212Not yet recruiting
Cannabis Clinic for People With Early Psychosis

This trial tests a specialized cannabis clinic designed to help people cut back or stop using cannabis if they've had a first episode of psychosis. The goal is to see if the clinic helps reduce cannabis use and improve mental health.

London
NCT04789915Recruiting· Phase 1
Testing memantine added to dopamine-targeting treatment for early psychosis

This Phase 1 study tests whether adding memantine can improve “negative symptoms” (like low motivation, reduced emotional expression) in people having their first episode of psychosis. It’s designed to understand safety and early effects when dopamine-related treatment is adjusted.

Glostrup Municipality, Capitol Region
NCT07434973Not yet recruiting· Phase 3
Early psychosis prevention with cannabidiol (CBD)

This trial tests if cannabidiol (a non-psychoactive cannabis component) can prevent psychosis in people ages 12-35 at high risk. It compares CBD to a placebo to see if it reduces symptoms and delays or prevents a first psychotic episode.

Vienna
NCT04411225Recruiting· Phase 3
CBD may help early psychosis along with usual treatment

This Phase 3 trial tests whether taking cannabidiol (CBD) can reduce symptoms when added to standard care for early psychosis (like first-episode psychosis or attenuated psychosis). It may help some people have fewer troubling thoughts or perceptions over time.

La Jolla, California
NCT05867849Recruiting· Phase 3
Cannabidiol treatment for bipolar depression symptoms

This trial tests whether cannabidiol (CBD) can reduce symptoms of bipolar depression. You may be eligible if you have bipolar I or II and a current depressive episode while staying on approved mood-stabilizing or antipsychotic medication.

Vancouver, British Columbia

Hear when a new Psychosis trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.